ATAI - atai Life Sciences to begin human trial for its MDMA derivative EMP-01 to treat PTSD

• atai Life Sciences ( NASDAQ: ATAI ) said on Tuesday its Phase 1 study to develop EMP-01 to treat post-traumatic stress disorder (PTSD) had received regulatory and ethics approvals from Medsafe and HDEC to begin participant enrollment.
• ( ATAI ) has risen ~4% before the bell.
• The drug will be orally administered in 32 healthy volunteers.
• EMP-01 is a 3,4-methylenedioxy-methamphetamine (MDMA) derivative under development for the treatment of post-traumatic stress disorder and other indications.

For further details see: